Summary by Moomoo AI
Aurora Cannabis reported strong Q2 fiscal 2025 results with total revenue reaching $81.1 million, up 29% YoY, driven by 41% growth in global medical cannabis and 21% growth in plant propagation. The company achieved record adjusted EBITDA of $10.1 million, a 210% increase YoY. Medical cannabis revenue grew to $61.3 million, with international revenue surpassing Canadian medical revenue for the first time at $35 million.The company maintained robust financial health with approximately $152 million in cash and a debt-free cannabis business. Adjusted gross margin before fair value adjustments was 54%, up from 51% in the prior year, while medical cannabis gross margins reached 68%. The company's strategic focus on high-margin medical markets, particularly in Australia, Germany, Poland, and the UK, contributed to the strong performance.Looking ahead to Q3 2025, Aurora expects continued strong revenue and margins in its global medical cannabis business, supported by growth in Europe and Australia. The company remains committed to achieving positive free cash flow by December 31, 2024, while maintaining operational excellence and strategic growth initiatives.
